← Human Trials & Peer-Reviewed Studies

Expulsion of Nova-T380, Multiload 375, and Copper-T380A contraceptive devices inserted during cesarean delivery.

Plain-language guide to PMID 25975871 (2015): randomized controlled trial of Copper (Supplement).

Key Facts

PMID
25975871
Journal
International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics
Year
2015
Study type
Randomized Controlled Trial
Authors
Ragab A et al. (7 authors)
DOI
10.1016/j.ijgo.2015.03.025

What This Study Did, in Plain Language

What Was Tested

Researchers studied Copper (Supplement) in this randomized controlled trial publication.

To compare the expulsion rate of Nova-T380, Multiload 375, and Copper-T380A intrauterine contraceptive devices (IUCDs) inserted during cesarean delivery.

Who Took Part

PubMed indexes the participants as young adults and adults, women only.

All women scheduled for an elective cesarean and accepting intraoperative insertion of an IUCD were randomly allocated to receive the Nova-T380 (group 1), Multiload 375 (group 2), or Cu-T380A (group 3) using a computer-generated table.

Researchers and participants were not masked to the type of IUCD.

How the Study Was Run

In design terms this was a randomized study.

The participants were allocated by chance, so the Copper (Supplement) group and the comparison group should start out alike.

A comparative randomized study was conducted between January 1, 2013, and June 30, 2014, in three maternity centers in Egypt and Saudi Arabia.

The primary outcome was IUCD expulsion (complete or partial [i.e. displacement]).

What Was Measured

The subject headings attached to it are Cesarean Section, Egypt, Intrauterine Device Expulsion, Intrauterine Devices, Copper, Risk and Saudi Arabia.

The authors tagged it with the keywords Cesarean delivery, Copper-T380A, Intrauterine contraceptive device, Multiload 375, Nova-T380 and Postpartum insertion.

What This Means in Plain Language

The paper is a randomized study of Copper (Supplement).

Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2015 (International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics), a journal based in United States.

More context: the Copper (Supplement) compound page, all human trials.

Our Notes on the Compound

Copper (Supplement): The active site of cytochrome c oxidase is described as containing copper ions that are essential for electron transfer.

Related Pages

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.